How to Choose a Sterile Fill-Finish CDMO

The short answer: Choose a sterile fill–finish CDMO on aseptic technology and Annex 1 readiness first — modern barrier systems (isolators or RABS) and a contamination-control strategy that meets the revised EU GMP Annex 1, because for a sterile product contamination control is the whole job. Then match container-closure and format (vials, prefilled syringes, cartridges) and any lyophilisation need to your product, confirm the quality control that surrounds the fill (visual inspection, container-closure integrity testing, environmental monitoring, and successful media fills), and weight the site's regulatory and inspection record more heavily than for any other modality — a sterility failure is the most serious kind. Get the fill format and scale right for both clinical and commercial volumes so you are not forced into a disruptive transfer later.

Sterile fill–finish is where a drug substance becomes an injectable a patient receives directly into the body, with no further processing to catch a problem. That makes it the least forgiving step in the chain and the one where the CDMO's quality culture, not just its equipment, decides the outcome. This guide covers how to select for it.

Why sterile fill-finish is a category of its own

Every other manufacturing step has downstream chances to detect and correct a defect. Aseptic filling does not — the product is filled, sealed, and released for injection. A single contamination event can mean a recall, a supply interruption, or worse. The regulatory expectations are correspondingly the highest of any drug-product step, and the revised EU GMP Annex 1 has raised them further, making a formal contamination-control strategy and barrier technology the baseline rather than a differentiator. Select accordingly: this is a decision about assurance, not throughput.

1. Assess aseptic technology and Annex 1 readiness

The single most important question is how the CDMO keeps the process sterile:

Barrier systems. Modern aseptic filling uses isolators or restricted access barrier systems (RABS) to separate operators from the product. A conventional open cleanroom line is increasingly hard to defend for a new program.
A contamination-control strategy (CCS) that meets Annex 1 — a documented, holistic view of every contamination risk and its control, not a set of disconnected SOPs.
Environmental monitoring and a demonstrated state of control, evidenced over time.

Ask directly how the line is configured and how they have responded to Annex 1; the answer separates a modern sterile operation from a legacy one.

2. Match container-closure, format, and lyophilisation

The fill has to fit your product and its market:

Format — vials, prefilled syringes, or cartridges each need different equipment and expertise; a partner strong in vials is not automatically strong in syringes.
Container-closure system compatibility with your formulation, and the data to support it.
Lyophilisation — if your biologic or peptide must be freeze-dried, confirm real lyo capability and capacity, which is a specialised and often bottlenecked resource.

Getting this wrong forces either a compromise on presentation or a change of partner.

3. Verify the quality control around the fill

Sterility assurance is a system, not a single step. Confirm the CDMO's capability in:

Aseptic process simulation (media fills) — a clean, current record is direct evidence the process is under control,
Container-closure integrity testing (CCIT) to prove the seal is a barrier,
Visual inspection (manual, semi- or fully automated) sized to your volumes, and
the analytical and microbiological release testing a sterile product requires.

Thin capability in any of these is where a sterile program fails, usually at inspection.

4. Weight the regulatory and inspection record most heavily here

For sterile products the compliance history is not one input among many — it is close to decisive. A site's aseptic performance is exactly what regulators scrutinise, and a Form 483 or Warning Letter citing sterility assurance, data integrity or environmental control at a fill–finish site is a far stronger signal than the same finding elsewhere. Check the specific site's FDA record and its EU/UK GMP status, read as a pattern over time, and weigh an open sterility-related finding as a walk-away until remediation is proven.

5. Fit capacity to both clinical and commercial

Finally, match scale and flexibility:

Clinical-scale flexibility for small, variable early batches, and
Commercial capacity and format headroom for your launch forecast,

so the same partner — or a deliberately planned technology transfer — carries you from first-in-human to commercial supply without an unplanned change at the worst moment.

Common pitfalls

Choosing on capacity or price for a step where sterility assurance is the real product.
Overlooking Annex 1 readiness and barrier technology on a new program.
Assuming vial expertise transfers to syringes or that lyophilisation capacity is available when it is a common bottleneck.
Under-weighting a sterility-related inspection finding that would be minor elsewhere but is critical here.

Where this fits

Sterile fill–finish selection is CDMO selection with the compliance dial turned to maximum. It is frequently the final step for a biologic or other injectable, so plan it as part of the whole drug-product path rather than as an afterthought.

PharmaTek links fill–finish and CDMO capabilities to each company's GMP and FDA compliance record across a directory of 22,000+ pharmaceutical companies and manufacturers, so a sterile shortlist can be screened for exactly the compliance signals that matter most here.

Frequently asked questions

What matters most when choosing a sterile fill-finish CDMO? Aseptic technology and contamination control. For an injectable there is no step after the fill to catch a problem, so the priority is modern barrier technology (isolators or RABS) and an Annex 1-compliant contamination-control strategy, backed by a clean media-fill and inspection record. Container-closure format, lyophilisation capability and capacity matter next; price and throughput are the last consideration, not the first.

What is EU GMP Annex 1 and why does it matter for fill-finish? Annex 1 is the EU Good Manufacturing Practice guidance for sterile medicinal products, revised to raise expectations around a formal, holistic contamination-control strategy and barrier technology such as isolators and RABS. It effectively makes modern aseptic engineering the baseline for sterile manufacturing, so a fill–finish CDMO's Annex 1 readiness is a core selection criterion rather than a bonus.

How important is a CDMO's inspection record for sterile products? More important than for any other modality. Regulators scrutinise aseptic performance closely, and a Form 483 or Warning Letter citing sterility assurance, environmental control or data integrity at a fill–finish site is a far stronger negative signal than the same finding elsewhere. Read the specific site's FDA and EU/UK GMP history as a pattern, and treat an open sterility-related finding as a walk-away until remediation is proven.

Does a CDMO strong in vials also handle prefilled syringes? Not necessarily. Vials, prefilled syringes and cartridges use different filling equipment and require different expertise, so confirm the CDMO has demonstrated capability in your specific format. The same applies to lyophilisation, which is a specialised and frequently bottlenecked resource — verify real capacity, not just a freeze-dryer on site.

What quality controls should surround aseptic filling? A sterility-assurance system: successful aseptic process simulations (media fills) as evidence of control, container-closure integrity testing to prove the seal, visual inspection sized to your batch volumes, environmental monitoring, and the microbiological and analytical release testing a sterile product requires. Weakness in any of these is where sterile programs typically fail, usually at inspection.

Sourcing a sterile fill-finish partner? Explore the supplier directory or book a demo to screen candidates against live GMP and FDA compliance data.